Citius Oncology, Inc.
CTOR
$2.09
$0.2010.58%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.56% | 29.60% | 49.36% | 38.05% | 159.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.83% | 59.25% | 39.53% | 32.22% | 79.16% |
| Operating Income | -6.83% | -59.25% | -39.53% | -32.22% | -79.16% |
| Income Before Tax | -10.30% | -59.25% | -39.53% | -32.22% | -79.16% |
| Income Tax Expenses | 83.47% | 83.47% | 83.47% | 0.00% | 0.00% |
| Earnings from Continuing Operations | -12.51% | -59.98% | -40.86% | -31.33% | -74.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.51% | -59.98% | -40.86% | -31.33% | -74.99% |
| EBIT | -6.83% | -59.25% | -39.53% | -32.22% | -79.16% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -6.08% | -50.98% | -33.00% | -27.05% | -75.00% |
| Normalized Basic EPS | -3.96% | -50.46% | -31.84% | -28.05% | -79.50% |
| EPS Diluted | -6.08% | -50.98% | -33.00% | -27.05% | -75.00% |
| Normalized Diluted EPS | -3.96% | -50.46% | -31.84% | -28.05% | -79.50% |
| Average Basic Shares Outstanding | 6.00% | 6.00% | 6.00% | 3.28% | 0.00% |
| Average Diluted Shares Outstanding | 6.00% | 6.00% | 6.00% | 3.28% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |